“There are mainly two indications. The first is Peyronie’s disease, for which we receive support from RegenLab through the PISANO PHRC study. The second is erectile dysfunction. These are the two main indications; in both cases, they relate to men’s intimate health.”

“That’s a very good question. The idea is really to have a comprehensive approach to patient care. Therefore, I discuss it from the very first consultations so that we can be completely transparent and ensure that patients have all the information they need to understand their therapeutic options.

Patient management should be comprehensive and truly sequential. The philosophy of our department is to be as inclusive as possible in explaining the expected benefits and, depending on the patient’s wishes, determining how far we will go in terms of medical or surgical intervention.”

“That’s a very good question. What I appreciate about RegenLab is the standardization of the products and the support provided, which is extremely important because we are not left on our own. I also value the scientific approach.

One of the challenges I encountered at the beginning of my training in regenerative medicine was that there was sometimes an overly commercial aspect, if I may choose my words carefully. What I appreciate about RegenLab is that we can rely on both the scientific support and the ethical commitment of the company.

As I often say, medicine is an art, but it must also be grounded in science. We need to understand the scientific basis of what we do and provide patients with the very best of current knowledge. That is part of our professional and ethical responsibility as physicians.”

“That is also a very good question. First and foremost, the benefit I have observed is pain reduction, particularly in Peyronie’s disease. I have also observed improvements in erectile function in patients with erectile dysfunction, as well as in patients with Peyronie’s disease who have associated erectile dysfunction.

At this stage, however, I do not measure these benefits in strictly scientific terms because I do not yet have enough long-term follow-up data, nor the scientific background required to state that the evidence fully supports my observations. This is precisely why the studies we are currently developing are so important.

Today, the main benefit lies with the patient: reassuring them that they are being supported and showing them that we are exploring every possible medical option before moving on to more invasive surgical procedures, or sometimes in combination with such procedures, which may be more durable in the long term.

PRP therefore remains an adjunctive therapy. It helps patients progress in their decision-making process and supports them throughout their treatment journey.”